NASH Observatory 2025 - Page 6 Of 38

NASH Observatory

Getting to the heart of NAFLD/NASH – the CVD perspective

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.

ByDr. D. Beard
OnMay 9, 2022

NASH Observatory Commented Articles

NAFLD and MAFLD as emerging causes of hepatocellular carcinoma

Hepatocellular carcinoma is the most common type of liver cancer, increasingly arising in patients with NAFLD or MAFLD. S. Myers et al. (University of Geneva, Switzerland) assessed all patients with hepatocellular carcinoma between 1990 and 2014 in the canton of Geneva....

ByDr. G. Bozet, MD
OnMay 9, 2022

NASH Observatory Commented Articles

Liver transplant recipients: NASH is frequent

To investigate incidence and predictors of NAFLD and NASH by employing noninvasive testing in liver transplant recipients (i.e. controlled attenuation parameter and cytokeratin 18), A. Alhinai et al. (McGill University, Montreal, Canada) prospectively...

ByDr. D. Beard
OnMay 9, 2022

NASH Observatory Commented Articles

Non-obese MAFLD is associated with colorectal adenoma

Colorectal adenoma is linked to metabolic dysfunction. S. Fukunaga et al. (Kurume University School of Medicine, Japan) aimed to investigate the impact of MAFLD on the prevalence of colorectal adenoma by comparing it to NAFLD in health check-up examinees in a multicenter retrospective study....

ByDr. G. Bozet, MD
OnMay 4, 2022

NASH Observatory Commented Articles

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

According to this article by D. Pfister et al. (German Cancer Research Center, Germany), the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH). This might be due to the amount or quality of viral antigens....

ByDr. D. Beard
OnMay 4, 2022

NASH Observatory Commented Articles

NASH: bariatric surgery and major adverse liver and cardiovascular outcomes

In this retrospective cohort study of 1158 patients with biopsy-proven fibrotic NASH without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes and major adverse cardiovascular events. For the authors, in this study....

ByDr. G. Bozet, MD
OnApril 28, 2022

NASH Observatory Commented Articles

Pathogenesis of NASH and dynamic changes in liver macrophages

Macrophage-mediated inflammation is critical in the pathogenesis of NASH. T-cell immunoglobulin domain and mucin domain-4 (TIM-4) is selectively expressed on antigen-presenting cells and modulates various immune responses. However, the role of TIM-4 expressed by Kupffer cells in liver fibrosis remains unclear....

ByDr. D. Beard
OnApril 28, 2022

NASH Observatory Commented Articles

NAFLD: progressive liver fibrosis

The progression of NASH was initially defined according to a two-hit model involving an initial development of steatosis, followed by a process of lipid peroxidation and inflammation. In contrast, current evidence proposes a "multi-hit" or "multi-parallel hit" model that includes multiple pathways....

ByDr. G. Bozet, MD
OnApril 25, 2022

NASH Observatory Commented Articles

NAFLD risk may be associated to dementia and cognitive decline in older age

The present study aimed to investigate the relationship between NAFLD risk and a dementia diagnosis in a large population-based sample aged >65 years. These findings suggest that “an increased NAFLD risk may be associated to dementia and cognitive decline in older age....

ByDr. D. Beard
OnApril 25, 2022

NASH Observatory

Non-Invasive Evaluation of NAFLD Severity

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are a leading cause of liver diseases worldwide, including hepatocellular carcinoma (HCC). In this review on non-invasive evaluation, Prof. Jérôme Boursier, France, presents a meta analysis focusing on the identification of patients with high risk profile and in need of specific management. Dr. Boursier reviews the two major families of non-invasive tests and discusses the sequential use of tests recommended in the EASL guidelines 2021.

ByProf. Jérôme Boursier
OnApril 22, 2022

NASH Observatory Commented Articles

Advancing the global public health agenda for NAFLD

In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations. The resulting consensus statements and recommendations address a broad range of topics that have general relevance for policymakers, health-care practitioners, civil society groups, research institutions....

ByDr. G. Bozet, MD
OnApril 20, 2022

NASH Observatory Commented Articles

NASH: mobile health intervention for lifestyle modification

Lifestyle modification designed to achieve sustained, modest weight loss remains hopelessly difficult to accomplish for many of patients with NAFLD. Mobile health application use to augment current educational practices will achieve meaningful dietary change and regular physical activity

ByDr. D. Beard
OnApril 20, 2022